Zurich (CH) / Greifswald (DE), December 15, 2017 – In a formal ceremony at the DKSH headquarters in Zurich, DKSH and CHEPLAPHARM Arzneimittel GmbH have signed a strategic partnership for a regional cooperation in several countries in Asia.
With its latest acquisitions, CHEPLAPHARM has recently further extended and diversified its product portfolio. DKSH has now been appointed to actively manage and promote CHEPLAPHARM’s branded products in selected markets in Asia, for example in Thailand, Malaysia, Singapore, Myanmar, Cambodia, Hong Kong and Macau. Besides serving the patients‘ needs in these markets, it is also the target of this cooperation to boost the company‘s presence within this important region.
DKSH is the leading Market Expansion Services Group with a focus on Asia, supporting companies to grow their business in new or existing markets. Their dedicated team of experts provides a broad spectrum of integrated Market Expansion Services across the entire value chain. In order to realize and further develop our ambitious growth strategy and to benefit from DKSH’s in-depth knowledge of the local markets and their well-established distribution network across Asia which allows them to provide regional solutions by duplicating success across markets, CHEPLAPHARM has stepped into this strategic collaboration.
CHEPLAPHARM’s Management Board: "We are very impressed by and highly value DKSH’s experience and expertise in Asia and are looking forward to mutually develop and foster a close, trustful and professional partnership with our new business partners."
"We have come to know CHEPLAPHARM as a company with great potential. With the largest dedicated salesforce in Asia and an unwavering commitment to quality and compliance, we are keen to drive sales for our new partner CHEPLAPHARM," said Bijay Singh, Head, Business Unit Healthcare, DKSH.
Press Office:
CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | presse(at)cheplapharm.com